Continuous infusion of oxalate by minipumps induces calcium oxalate nephrocalcinosis

Urological Research

Volumn 34, Issue 3, 2006, Pages 200-210

  Marengo, Susan Ruth ^a   Chen, Daniel H C ^a   Evan, Andrew P ^b   Sommer, Andre J ^c   Stowe, Nicholas T ^a   Ferguson, Donald G ^a   Resnick, Martin I ^a   MacLennan, Gregory T ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c MIAMI UNIVERSITY   (United States)

Author keywords

Calcium; Nephrocalcinosis; Nephrolithiasis; Oxalate; Oxalosis; Rat

Indexed keywords

CALCIUM OXALATE; OXALIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYSTAL; CRYSTALLURIA; FROZEN SECTION; HYPEROXALURIA; INFRARED SPECTROSCOPY; INFUSION; JEJUNOILEAL BYPASS; KIDNEY CALCIFICATION; KIDNEY COLLECTING TUBULE; KIDNEY CORTEX; KIDNEY MEDULLA; MALE; MINIPUMP; NEPHROLITHIASIS; NONHUMAN; PRIORITY JOURNAL; RAT; URINALYSIS; URINARY EXCRETION; UROTHELIUM;

ANIMALS; C-REACTIVE PROTEIN; CALCIUM OXALATE; CRYSTALLIZATION; INFUSION PUMPS, IMPLANTABLE; KIDNEY; MALE; NEPHROCALCINOSIS; OXALATES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33646731309     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00240-006-0043-7     Document Type: Article

References (60)

1. Milliner DS, Wilson DM, Smith LH (2001) Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. Kidney Int 59:31
2. Bohles H, Beifuss OJ, Brandl U, Pichl J, Akcetin Z, Demling L (1988) Urinary factors of kidney stone formation in patients with Crohn's disease. Klin Wochenschr 66:87
3. Hocking MP, Duerson MC, O'Leary JP, Woodward ER (1983) Jejunoileal bypass for morbid obesity. Late follow-up in 100 cases. N Engl J Med 308:995
4. Annuk M, Backman U, Holmgren K, Vessby B (1998) Urinary calculi and jejunoileal bypass operation. A long-term follow-up. Scand J Urol Nephrol 32:177
5. Perez-Brayfield MR, Caplan D, Gatti JM, Smith EA, Kirsch AJ (2002) Metabolic risk factors for stone formation in patients with cystic fibrosis. J Urol 167:480
6. Curhan GC, Willett WC, Speizer FE, Stampfer MJ (2001) Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 59:2290
7. Asplin JR, Parks JH, Chen MS, Lieske JC, Toback FG, Pillay SN, Nakagawa Y, Coe FL (1999) Reduced crystallization inhibition by urine from men with nephrolithiasis. Kidney Int 56:1505
8. Menon M, Resnick MI (2002) Urinary lithiasis: etiology, diagnosis, and medical management. In: Walsh PC (ed) Campbell's urology, 8th edn. Saunders, Philadelphia, p 2229
9. Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB, Shao Y, Sommer AJ, Paterson RF, Kuo RL, Grynpas M (2003) Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 111:607
10. Vermeulen CW, Lyon ES (1968) Mechanisms of genesis and growth of calculi. Am J Med 45:684
11. Khan SR, Finlayson B, Hackett RL (1983) Experimental induction of crystalluria in rats using mini-osmotic pumps. Urol Res 11:199
12. Khan SR, Finlayson B, Thomas WCJ, Hackett RL (1984) Relationship between experimentally induced crystalluria and relative supersaturation of various stone salts in rats. Urol Res 12:271
13. Holmes RP, Ambrosius WT, Assimos DG (2005) Dietary oxalate loads and renal oxalate handling. J Urol 174:943
14. Finlayson B, Reid F (1978) The expectation of free and fixed particles in urinary stone disease. Invest Urol 15:442
15. Thamilselvan S, Khan SR, Menon M (2003) Oxalate and calcium oxalate mediated free radical toxicity in renal epithelial cells: effect of antioxidants. Urol Res 31:3
16. Jonassen JA, Cao LC, Honeyman T, Scheid CR (2003) Mechanisms mediating oxalate-induced alterations in renal cell functions. Crit Rev Eukaryot Gene Expr 13:55
17. Chaturvedi LS, Kou IS, Sekhon A, Bhandari A, Menon M, Koul HK (2002) Oxalate selectively activates p38 mitogen-activated protein kinase and c-Jun N-terminal kinase signal transduction pathways in renal epithelial cells. J Biol Chem 277:13321
18. Khan SR, Thamilselvan S (2000) Nephrolithiasis: a consequence of renal epithelial cell exposure to oxalate and calcium oxalate crystals. Mol Urol 4:305
19. Scheid CR, Koul HK, Kennington L, Hill WA, Luber-Narod J, Jonassen J, Honeyman T, Menon M (1995) Oxalate-induced damage to renal tubular cells. Scanning Microsc 9:1097
20. Wiessner JH, Hasegawa AT, Hung LY, Mandel NS (1999) Oxalate-induced exposure of phosphatidylserine on the surface of renal epithelial cells in culture. J Am Soc Nephrol 10:S441
21. Verkoelen CF, van der Boom BG, Houtsmuller AB, Schroder FH, Romijn JC (1998) Increased calcium oxalate monohydrate crystal binding to injured renal tubular epithelial cells in culture. Am J Physiol 274:F958
22. Wiessner JH, Hasegawa AT, Hung LY, Mandel GS, Mandel NS (2001) Mechanisms of calcium oxalate crystal attachment to injured renal collecting duct cells. Kidney Int 59:637
23. Fasano JM, Khan SR (2001) Intratubular crystallization of calcium oxalate in the presence of membrane vesicles: an in vitro study. Kidney Int 59:169
24. Marengo SR, Chen DH-C, MacLennan GT, Resnick MI, Jacob GH (2004) Minipump induced hyperoxaluria and crystal deposition in rats: a model for calcium oxalate urolithiasis. J Urol 171:1304
25. Yasue T (1969) Histochemical identification of calcium oxalate. Acta Histochem Cytochem 2:83
26. Anderson JC, Dellomo JM, Sommer AJ, Evan AP, Bledsoe SB (2005) A concerted protocol for the analysis of mineral deposits in biopsied tissue using infrared microanalysis. Urol Res (in press)
27. Anderson J, Dellomo J, Sommer A, Evan A, Bledsoe S (2005) A concerted protocol for the analysis of mineral deposits in biopsied tissue using infrared microanalysis. Urol Res 33:213
28. Wilhelm SM, Stowe NT, Robinson AV, Schulak JA (2001) The use of the endothelin receptor antagonist, tezosentan, before or after renal ischemia protects renal function. Transplantation 71:211
29. Hirschfield GM, Pepys MB (2003) C-reactive protein and cardiovascular disease: new insights from an old molecule. Q J Med 96:793
30. Szalai AJ (2002) The biological functions of C-reactive protein. Vascul Pharmacol 39:105
31. Diaz Padilla N, Bleeker WK, Lubbers Y, Rigter GM, Van Mierlo GJ, Daha MR, Hack CE (2003) Rat C-reactive protein activates the autologous complement system. Immunology 109:564
32. de Beer FC, Baltz ML, Munn EA, Feinstein A, Taylor J, Bruton C, Clamp JR, Pepys MB (1982) Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology 45:55
33. Evan AP, Bledsoe SB, Connors BA, Deng L, Liang L, Shao C, Fineberg NS, Grynpas MD, Stambrook PJ, Youzhi S, Sahota A, Tischfield JA (2001) Sequential analysis of kidney stone formation in the Aprt knockout mouse. Kidney Int 60:910
34. Fan J, Chandhoke PS, Grampsas SA (1999) Role of sex hormones in experimental calcium oxalate nephrolithiasis. J Am Soc Nephrol 10:S376
35. Poldelski V, Johnson A, Wright S, Rosa VD, Zager RA (2001) Ethylene-glycol-mediated tubular injury:identification of critical metabolites and injury pathways. Am J Kidney Dis 38:339
36. Khan SR (1995) Animal model of calcium oxalate nephrolithiasis. In: Khan SR (ed) Calcium oxalate in biological systems. CRC Press Inc., New York, p 343
37. Fan J, Glass MA, Chandhoke PS (1998) Effect of castration and finasteride on urinary oxalate excretion in male rats. Urol Res 26:71
38. Asselman M, Verhulst A, De Broe ME, Verkoelen CF (2003) Calcium oxalate crystal adherence to hyaluronan-, osteopontin-, and CD44-expressing injured/regenerating tubular epithelial cells in rat kidneys. J Am Soc Nephrol 14:3155
39. Bushinsky DA, Asplin JR, Grynpas MD, Evan AP, Parker WR, Alexander KM, Coe FL (2002) Calcium oxalate stone formation in genetic hypercalciuric stone-forming rats. Kidney Int 61:975
40. O'Connor RC, Worcester EM, Evan AP, Meehan S, Kuznetsov D, Laven B, Sommer AJ, Bledsoe SB, Parks JH, Coe FL, Grynpas M, Gerber GS (2005) Nephrolithiasis and nephrocalcinosis in rats with small bowel resection. Urol Res 33:105
41. Costello JF, Smith M, Stolarski C, Sadovnic MJ (1992) Extrarenal clearance of oxalate increases with progression of renal failure in the rat. J Am Soc Nephrol 3:1098
42. Sugimoto T, Osswald H, Yamamoto K, Kanazawa T, Iimori H, Funae Y, Kamikawa S, Kishimoto T (1993) Fate of circulating oxalate in rats. Eur Urol 23:485
43. Green ML, Hatch M, Freel RW (2005) Ethylene Glycol Induces Hyperoxaluria without metabolic acidosis in rats. Am J Physiol Renal Physiol 289:F536
44. Thamilselvan S, Menon M (2005) Vitamin E therapy prevents hyperoxaluria-induced calcium oxalate crystal deposition in the kidney by improving renal tissue antioxidant status. BJU Int 96:117
45. Wareing M, Green R (1994) Effect of formate and oxalate on fluid reabsorption from the proximal convoluted tubule of the anaesthetized rat. J Physiol 477:347
46. Khan SR, Shevock PN, Hackett RL (1989) Urinary enzymes and calcium oxalate urolithiasis. J Urol 142:846
47. Pirulli D, Marangella M, Amoroso A (2003) Primary hyperoxaluria: genotype-phenotype correlation. J Nephrol 16:297
48. Parks JH, Worcester EM, O'Connor RC, Coe FL (2003) Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int 63:255
49. de Water R, Boeve ER, van Miert PPMC, Deng G, Cao LC, Stijnen T, de Bruijn WC, Schroder FH (1996) Experimental nephrolithiasis in rats: the effect of ethylene glycol and vitamin D3 on the induction of renal calcium oxalate crystals. Scanning Microsc 10:591
50. Umekawa T, Hatanaka Y, Kurita T, Khan SR (2004) Effect of angiotensin II receptor blockage on osteopontin expression and calcium oxalate crystal deposition in rat kidneys. J Am Soc Nephrol 15:635
51. Toblli JE, Ferder L, Stella I, De Cavanaugh EM, Angerosa M, Inserra F (2002) Effects of angiotensin II subtype 1 receptor blockade by losartan on tubulointerstitial lesions caused by hyperoxaluria. J Urol 168:1550
52. Coe FL, Parks JH, Asplin JR (1992) The pathogenesis and treatment of kidney stones. NEJM 327:1141
53. Monico CG, Persson M, Ford GC, Rumsby G, Milliner DS (2002) Potential mechanisms of marked hyperoxaluria not due to primary hyperoxaluria I or II. Kidney Int 62:392
54. Khan SR (1995) Mechanisms involved in calcium oxalate nephrolithiasis based on studies in an animal model. Ital J Miner Electrolyte Metab 9:3
55. Mole DR, Tomson CR, Mortensen N, Winearls CG (2001) Renal complications of jejuno-ileal bypass for obesity. QJM 94:69
56. Hassan I, Juncos LA, Milliner DS, Sarmiento JM, Sarr MG (2001) Chronic renal failure secondary to oxalate nephropathy: a preventable complication after jejunoileal bypass. Mayo Clin Proc 76:758
57. Drenick EJ, Stanley TM, Border WA, Zawada ET, Dornfeld LP, Upham T, Llach F (1978) Renal damage with intestinal bypass. Ann Intern Med 89:594599
58. Hicks K, Evans GB, Rogerson ME, Bass P (1998) Jejuno-ileal bypass, enteric hyperoxaluria, and oxalate nephrosis: a role for polarised light in the renal biopsy. J Clin Pathol 51:700
59. Mandel N, Mandel I, Fryjoff K, Rejniak T, Mandel G (2003) Conversion of calcium oxalate to calcium phosphate with recurrent stone episodes. J Urol 169:2026
60. Parks JH, Worcester EM, Coe FL, Evan AP, Lingeman JE (2004) Clinical implications of abundant calcium phosphate in routinely analyzed kidney stones. Kidney Int 66:777